Altria Group Plans to Sell 35 Million Shares of AB InBev

Business by 2FIRSTS.ai

Mar.15.2024

Altria Group Plans to Sell 35 Million Shares of AB InBev

Altria Group plans to sell 35 million shares of Anheuser-Busch InBev for $2.26 billion, reducing its stake to 10%.

According to Reuters on March 14th, Altria Group plans to sell 35 million shares of Anheuser-Busch InBev. Altria currently owns approximately 197 million shares of Anheuser-Busch InBev, representing a 10% stake in the company.

On the recent stock market closing day, the total value of this equity sale was $2.26 billion. Anheuser-Busch InBev plans to sell a portion of its American depositary shares of Budweiser in the United States, as well as conduct a private placement in the European Economic Area and the United Kingdom.

Altria Group announced that Anheuser-Busch InBev has agreed to repurchase $2 billion worth of common stock directly from Altria after the equity offering concludes.

Altria Group owns several tobacco brands including Marlboro and the vape company NJOY, while Anheuser-Busch InBev is one of the largest beer producers in the world, headquartered in Belgium. It was formed by the merger of Anheuser-Busch and InBev in 2008. The company operates multiple well-known beer brands such as Budweiser, Corona, Stella Artois, and Hoegaarden. Anheuser-Busch InBev holds a significant market share globally and continues to expand its business operations.

References:

[1] Tobacco firm Altria to sell some AB InBev shares

Also Read:

[1] Altria Applies to FDA for Selling NJOY Fruit Flavors in 100,000 Stores by 2024

[2] Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023

[3] Altria Group's Q4 Earnings Impacted by Declining Cigarette Sales

#Europe #Traditional tobacco #Belgium #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved

Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.

Oct.11 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

Product | NEXA FLEX Releases “Built in the USA” Version, Says All Flavors Are Tailored for Adult U.S. Users

NEXA has introduced a disposable e-cigarette, NEXA FLEX, which is promoted as “Built in the USA,” highlighting domestic production and flavors developed for adult U.S. vaping consumers. The device retains features such as a transparent e-liquid chamber, Normal/Turbo dual modes, and up to 40,000 puffs, and is scheduled to launch in late November in Texas. Other brands, including SKE and FASTA, have also recently released products labeled as “Made in the USA” or “U.S.-assembled.”

Nov.20 by 2FIRSTS.ai

Vietnam’s Health Ministry Proposes Including E-Cigarettes and Heated Tobacco in the Investment Law Ban List

Vietnam’s Ministry of Health has submitted a proposal to the Government Office recommending that “e-cigarettes and heated tobacco products” be added to the list of prohibited investment and business sectors in the amended Investment Law. The proposal aligns with National Assembly Resolution No. 173/2024/QH15, which bans the production, trade, import, and use of these products starting in 2025.